• 1
    Janson C, Gislason T, De Backer W, Plaschke P, Bjornsson E, et al. Prevalence of sleep disturbance among young adults in three European countries. Sleep 1995; 18: 58997.
  • 2
    Wallander MA, Johansson S, Ruigomez A, Garcia Rodriguez LA, Jones R. Morbidity associated with sleep disorders in general practice: incidence, risk factors, associated with sleep disorders in primary care: a longitudinal cohort study. Prim Care Companion J Clin Psychiatry 2007; 9: 33845.
  • 3
    Shaker R, Castell DO, Schoenfeld PS, Spechler SJ. Nighttime heartburn is an under-appreciated clinical problem that impacts sleep and daytime function: the results of a Gallup survey conducted on behalf of the American Gastroenterological Association. Am J Gastroenterol 2003; 98: 148793.
    Direct Link:
  • 4
    Moayyedi P, Axon ATR. Review article: gastro-oesophageal reflux disease – the extent of the problem. Aliment Pharmacol Ther 2005; 22(Suppl. 1): 119.
  • 5
    Moayyedi P, Talley NJ. Gastro-oesophageal reflux disease. Lancet 2006; 367: 2086100.
  • 6
    Gerson LB, Fass R. A systematic review of the definitions, prevalence, and response to treatment of nocturnal gastroesophageal reflux disease. Clin Gastroenterol Hepatol 2009; 7: 3728.
  • 7
    Regenbogen E, Helkin A, Georgopoulos R, Vasu T, Shroyer AL. Esophageal reflux disease proton pump inhibitor therapy impact on sleep disturbance: a systematic review. Otolaryngol Head Neck Surg 2012; 146: 52432.
  • 8
    Johnson DA, Orr WC, Crawley JA, et al. Effect of esomeprazole on nighttime heartburn and sleep quality in patients with GERD: a randomized, placebo-controlled trial. Am J Gastroenterol 2005; 100: 191422.
    Direct Link:
  • 9
    Johnson D, Crawley JA, Hwang C, Brown K. Clinical trial: esomeprazole for moderate-to-severe nighttime heartburn and gastro-oesophageal reflux disease-related sleep disturbances. Aliment Pharmacol Ther 2010; 32: 18290.
  • 10
    Fass R, Johnson DA, Orr WC, et al. The effect of dexlansoprazole MR on nocturnal heartburn and GERD-related sleep disturbances in patients with symptomatic GERD. Am J Gastroenterol 2011; 106: 42131.
  • 11
    Hungin APS, Hill C, Raghunath A. Systematic review: frequency and reasons for consultation for gastro-oesophageal reflux disease and dyspepsia. Aliment Pharmacol Ther 2009; 30: 33142.
  • 12
    Jones R, Armstrong D, Malfertheiner P, Ducrotte P. Does the treatment of gastro- oesophageal reflux disease (GERD) meet patients' needs? A survey-based study. Curr Med Res Opin 2006; 22: 65762.
  • 13
    Armstrong D, Veldhuyzen SJ, Chung SA, Shapiro CM, Dhillon S, Escobedo S, et al. Validation of a short questionnaire in English and French for use in patients with persistent upper gastrointestinal symptoms despite proton pump inhibitor therapy: the PASS (Proton pump inhibitor Acid Suppression Symptom) test. Can J Gastroenterol 2005; 19: 3508.
  • 14
    Flook NW, Wiklund I. Accounting for the effect of GERD symptoms on patients' health-related quality of life: supporting optimal disease management by primary care physicians. Int J Clin Pract 2007; 61: 20718.
  • 15
    Flook NW. GERD: a fresh look at a common problem in primary care. J Fam Pract 2007; 56(Suppl.): 31a4a.
  • 16
    Veldhuyzen van Zanten SJ, Chiba N, Armstrong D, Barkun AN, Thomson AB, Mann V, et al. Validation of a 7-point Global Overall Symptom scale to measure the severity of dyspepsia symptoms in clinical trials. Aliment Pharmacol Ther 2006; 23: 5219.
  • 17
    Shaw MJ, Talley NJ, Beebe TJ, Rockwood T, Carlsson R, Adlis S, et al. Initial validation of a diagnostic questionnaire for gastro-esophageal reflux disease. Am J Gastroenterol 2001; 96: 527.
    Direct Link:
  • 18
    Wiklund IK, Junghard O, Grace E, Talley NJ, Kamm M, Veldhuyzen van Zanten S, et al. Quality of life in reflux and dyspepsia patients. Psychometric documentation of a new disease-specific questionnaire (QOLRAD). Eur J Surg Suppl 1998; 583: 419.
  • 19
    Campbell MK, Grimshaw JM. Cluster randomised trials: time for improvement. The implications of adopting a cluster design are still largely being ignored. BMJ 1998; 317: 11712.
  • 20
    Li J, Brackbill RM, Stellman SD, et al. Gastro-esophageal reflux symptoms and comorbid asthma and posttraumatic stress disorder following the 9/11 terrorist attacks on World Trade Center in New York City. Am J Gastroenterol 2011; 106: 193341.
  • 21
    Ing AJ, Ngu MC, Breslin A. Obstructive sleep apnea and gastro- esophageal reflux. Am J Med 2000; 108: 120S5S.
  • 22
    Guda N, Partington S, Vakil N. Symptomatic gastro-esophageal reflux, arousals and sleep quality in patients undergoing polysomnography for possible obstructive sleep apnoea. Aliment Pharmacol Ther 2004; 20: 11539.
  • 23
    Orr WC, Goodrich S, Robert J. The effect of acid suppression on sleep patterns and sleep-related gastro-esophageal reflux. Aliment Pharmacol Ther 2005; 21: 1038.
  • 24
    Katz PO, Anderson C, Khoury RM, et al. Gastro-oesophageal reflux associated with nocturnal acid breakthrough on proton pump inhibitors. Aliment Pharmacol Ther 1998; 12: 12314.
  • 25
    Bredenoord AJ. Mechanisms of reflux perception in gastro-esophageal reflux disease: a review. Am J Gastroenterol 2012; 107: 815.
  • 26
    Kahrilas PJ, Howden CW, Hughes N. Response of regurgitation to proton pump inhibitor therapy in clinical trials of gastro-esophageal reflux disease. Am J Gastroenterol 2011; 106: 141925.
  • 27
    Dickman R, Parthasarathy S, Malagon IB, et al. Comparisons of the distribution of ooesophageal acid exposure throughout the sleep period among the different gastro-oesophageal reflux dis- ease groups. Aliment Pharmacol Ther 2007; 26: 418.
  • 28
    Moayyedi P, Armstrong D, Hunt RH, Lei Y, Bukoski M, White RJ. The gain in quality-adjusted life months by switching to esomeprazole in those with continued reflux symptoms in primary care: EncomPASS–a cluster-randomized trial. Am J Gastroenterol 2010; 105: 23416.
  • 29
    Spiegel BM. Treatment strategies for acid reflux: EncomPASSing practical solutions for primary care. Am J Gastroenterol 2010; 105: 23479.
  • 30
    Eldridge SM, Ashby D, Feder GS, Rudnicka AR, Ukoumunne OC. Lessons for cluster randomized trials in the twenty-first century: a systematic review of trials in primary care. Clin Trials 2004; 1: 8090.
  • 31
    Edwards SJ, Lind T, Lundell L. Systematic review: proton pump inhibitors (PPIs) for the healing of reflux oesophagitis - a comparison of esomeprazole with other PPIs. Aliment Pharmacol Ther 2006; 24: 74350.
  • 32
    Kinoshita Y, Hongo M; The Japan TWICE study group. Efficacy of twice daily rabeprazole for reflux esophagitis patients refractory to standard once daily administration of PPI: Japan-based TWICE study. Am J Gastroenterol 2012; 107: 52230.
  • 33
    Fass R. Healing erosive esophagitis with a proton pump inhibitor: the more the merrier? Am J Gastroenterol 2012; 107: 5313.
  • 34
    Peng S, Xiong LS, Xiao YL, et al. Prompt upper endoscopy is an appropriate initial management in uninvestigated Chinese patients with typical reflux symptoms. Am J Gastroenterol 2010; 105: 194752.
  • 35
    Dutta AK, Chacko A, Balekuduru A, Sahu MK, Gangadharan SK. High prevalence of significant endoscopic findings in patients with uninvestigated typical reflux symptoms. Am J Gastroenterol 2011; 106: 11723.
  • 36
    Lacy BE, Chehade R, Crowell MD. A prospective study to compare a symptom-based reflux disease questionnaire to 48-h wireless pH monitoring for the identification of gastro-esophageal reflux. Am J Gastroenterol 2011; 106: 160411.
  • 37
    Yi C-H, Hu C-T, Chen C-L. Sleep dysfunction in patients with GERD: erosive versus nonerosive reflux disease. Am J Med Sci 2007; 334: 16870.